5 unchanged sentences
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in the Company’s securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
−Removed: None of the Company's directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as each term is defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
+Added: The following table describes, for the third quarter of 2025, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
+Added: Name (Title) Action Taken (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities
+Added: Butler ( President and Chief Executive Officer )
+Added: August 19, 2025
+Added: Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan
+Added: Until November 16, 2026
+Added: Up to an aggregate of 702,562 shares
+Added: Butler ( President and Chief Executive Officer )
+Added: September 8, 2025 Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted
+Added: Until final settlement of any restricted stock units, or RSUs
+Added: Indeterminable (1)
+Added: Ostrowski ( Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer )
+Added: September 8, 2025 Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted
+Added: Until final settlement of any RSUs
+Added: Indeterminable (1)
+Added: Grund ( Senior Vice President, Chief Commercial Officer )
+Added: September 9, 2025 Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted
+Added: Until final settlement of any RSUs
+Added: Indeterminable (1)
+Added: Malabre ( Senior Vice President, Chief Accounting Officer )
+Added: September 8, 2025 Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all equity awards that have or may be granted
+Added: Until final settlement of any RSUs
+Added: Indeterminable (1)
Akebia Therapeutics, Inc.
| Form 10-Q | Page 109
+Added: (1) The number of shares subject to RSUs that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement.
+Added: This trading arrangement, which applies to RSUs whether vesting is based on the passage of time and/or the achievement of performance goals, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a RSU in an amount sufficient to satisfy the applicable tax withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable tax withholding obligation.
+Added: Akebia Therapeutics, Inc.
+Added: | Form 10-Q | Page 110
3.1 Ninth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (001-36352), filed on March 28, 2014).
2 unchanged sentences
3.3 Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (001-36352), filed on April 28, 2023).
−Removed: Akebia Therapeutics, Inc.
−Removed: 2023 Stock Incentive Plan , as amended (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K (00 1 -36352), filed on June 13, 2025).
+Added: Amendment #3 to the Supply Agreement by and between the Company and STA Pharmaceutical Hong Kong Limited dated August 15, 2025.
31.1* Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
9 unchanged sentences
* Filed, or submitted electronically, herewith
+Added: Indicates portions of the exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K
Akebia Therapeutics, Inc.
2 unchanged sentences
AKEBIA THERAPEUTICS, INC.
−Removed: August 7, 2025
+Added: November 10, 2025
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: August 7, 2025
+Added: November 10, 2025
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
(Principal Financial Officer)
−Removed: August 7, 2025
+Added: November 10, 2025
/s/ Richard C.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.